LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1
Not an actual patient.
*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).3
†Greater LDL-C reduction was maintained during each 6-month dosing interval vs placebo as a complement to a maximally tolerated statin.1
After a CV event, reaching and remaining at LDL-C target is critical4
CAD, coronary artery disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.